CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 7 enrolled
Drug / intervention
CBD/THC +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03805750
NCT03805750Phase 2Completed
CompareCT.gov

A Double-Blind, Cross-Over, Placebo- Controlled Efficacy and Tolerability Study of Oral Cannabidiol (CBD) and Tetrahydrocannabinol (THC) for Essential Tremor (ET).

University of California, San Diego·interventional·Posted Jan 16, 2019·Updated Oct 13, 2022

In Brief

A Phase 2 clinical trial evaluating CBD/THC and Placebo oral capsule for Essential Tremor. Completed, enrolled 7 participants across 1 site.

Detailed Summary

This is a pilot trial to evaluate the safety and efficacy of a combined oral formulation of THC and CBD in patients with Essential Tremor.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEssential Tremor
CountriesUnited States
CollaboratorsInternational Essential Tremor Foundation, Tilray, Center for Medicinal Cannabis Research

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedJan 16, 2019
Enrollment StartJan 22, 2019
Primary CompletionSep 1, 2020
Study CompletionNov 30, 2020
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 7.5 years ago

Interventions

CBD/THCdrug

Oral formulation of combined Cannabidiol (CBD) and Tetrahydrocannabinol (THC).

Placebo oral capsuledrug

Matched Placebo